XII/ECOG E2993 of more than 1500 patients from the international ALL trial: MRC UKALL Induction therapy for adults with acute lymphoblastic leukemia: results
نویسندگان
چکیده
Party Martin S. Tallman, Anthony H. Goldstone and for ECOG and the MRC/NCRI Adult Leukemia Working Hillard M. Lazarus, Ian M. Franklin, Mark R. Litzow, Niculae Ciobanu, H. Grant Prentice, Jill Durrant, Jacob M. Rowe, Georgina Buck, Alan K. Burnett, Raj Chopra, Peter H. Wiernik, Susan M. Richards, XII/ECOG E2993 of more than 1500 patients from the international ALL trial: MRC UKALL Induction therapy for adults with acute lymphoblastic leukemia: results
منابع مشابه
Outcome of adult acute lymphoblastic leukaemia following induction chemotherapy with modified MRC UKALL XII/ECOG E2993 protocol.
Cure rates for adult acute lymphoblastic leukaemia (ALL) in developing countries are significantly lower because of problems unique to these countries. Recent studies have reported complete response rates for any induction regimen of more than 90% in adult ALL patients. This study was conducted to evaluate the response rate of induction chemotherapy in adult ALL patients in the Department of Ha...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993
The international acute lymphoblastic leukemia (ALL) study was designed to prospectively define the optimal therapy for adults 60 years of age or younger with newly diagnosed ALL. All patients received identical induction therapy, and 91% achieved complete remission (CR). Patients 50 years of age or younger with a compatible sibling were assigned to undergo allogeneic transplantation; the other...
متن کاملInduction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993.
The international acute lymphoblastic leukemia (ALL) study was designed to prospectively define the optimal therapy for adults 60 years of age or younger with newly diagnosed ALL. All patients received identical induction therapy, and 91% achieved complete remission (CR). Patients 50 years of age or younger with a compatible sibling were assigned to undergo allogeneic transplantation; the other...
متن کاملIn adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993).
An international collaboration was set up to prospectively evaluate the role of allogeneic transplantation for adults with acute lymphoblastic leukemia (ALL) and compare autologous transplantation with standard chemotherapy. Patients received 2 phases of induction and, if in remission, were assigned to allogeneic transplantation if they had a compatible sibling donor. Other patients were random...
متن کاملGenetic lesions in chronic lymphocytic leukemia: what's ready for prime time use?
C hronic lymphocytic leukemia (CLL) is a frequent CD5 + B-cell neoplasia that involves peripheral blood, bone marrow, lymph nodes and other lym-phoid tissues. The median age of patients at diagnosis of CLL is around 70 years old and the prognosis is extremely variable. In spite of some advances in its therapy, CLL continues to be incurable. Due to this fact, and to the prognos-tic heterogeneity...
متن کامل